<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>10377650</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">37508945</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">10377650</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3390/brainsci13071014</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">brainsci-13-01014</article-id></all-ids><extracted-table><table-id>brainsci-13-01014-t001</table-id><table-label>Table 1</table-label><table-caption>Characteristics of trial participants at baseline.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="brainsci-13-01014-t001"><object-id pub-id-type="pii">brainsci-13-01014-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of trial participants at baseline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Intervention Groups</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination <break/>(<italic toggle="yes">n</italic> = 9)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard Care <break/>(<italic toggle="yes">n</italic> = 8)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control <break/>(<italic toggle="yes">n</italic> = 5)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median age (IQR)–year</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (26.0–43.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (37.3–56.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (50.0–61.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female sex–no. (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (56)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (60)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco smoker–no. (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coexisting conditions–no. (%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Good past health</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (89)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (50)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (40)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (13)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (40)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyperlipidaemia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Atherosclerotic diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rheumatological conditions</td><td align="center" valign="middle" rowspan="1" colspan="1">1 <sup>†</sup> (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malignancies</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 <sup>‡</sup> (40)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of haematological or solid organ transplantation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV-2 diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive RT–PCR–no. (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (100)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>T</sub> values (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.1 (18.1–29.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.1 (15.1–21.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.2 (15.7–22.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COVID–19 disease severity</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mild disease–no. (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (100)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">COVID–19-related OD, onset and duration (IQR)–days</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Onset of OD from first COVID–19 symptom</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 (0.0–7.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0 (1.8–16.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 (0.0–3.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median duration of COVID–19-related OD</td><td align="center" valign="middle" rowspan="1" colspan="1">159 (130.0–163.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">164.5 (118.3–180.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">138.0 (135.0–225.0)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">COVID–19-related OD, symptomatology–no. (%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OD onset</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sudden</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (67)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gradual</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (80)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OD characteristics</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anosmia</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (44)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (63)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (40)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyposmia</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (44)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (60)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Parosmia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (38)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyperosmia</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phantosmia <sup>※</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Olfactory assessments–mean (SD)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Modified LK score</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 (0.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BTT</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 (1.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SIT </td><td align="center" valign="middle" rowspan="1" colspan="1">24.6 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">24.5 (6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.6 (9.0)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">SIT category–no. (%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Normosmia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mild microsmia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Moderate microsmia</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (33)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Severe microsmia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (40)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anosmia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (40)</td></tr></tbody></table><table-wrap-foot><fn><p>Combination = oral vitamin A in combination with olfactory training (OT). Standard care = OT alone. Control = clinical observation. <sup>†</sup> Rheumatoid arthritis, quiescent disease. <sup>‡</sup> Malignancy of the breasts, in remission. <sup>※</sup> Phantosmia, detection of rotten substances or burning wood. BTT = butanol threshold test; COVID–19 = coronavirus disease 2019; C<sub>T</sub> = cycle threshold; Modified LK score = modified Lund-Kennedy endoscopic score; OD = olfactory dysfunction; RT–PCR = reverse transcription–polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SD = standard deviation; SIT = smell identification test.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>brainsci-13-01014-t001_Table 1Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Characteristics of trial participants at baseline.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin"/><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Intervention Groups</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin">Characteristics</th><th align="center" valign="middle" style="border-bottom:solid thin">Combination (n = 9)</th><th align="center" valign="middle" style="border-bottom:solid thin">Standard Care (n = 8)</th><th align="center" valign="middle" style="border-bottom:solid thin">Control (n = 5)</th></tr></thead><tbody><tr><td align="center" valign="middle">Median age (IQR)–year</td><td align="center" valign="middle">36 (26.0–43.0)</td><td align="center" valign="middle">49 (37.3–56.3)</td><td align="center" valign="middle">58 (50.0–61.0)</td></tr><tr><td align="center" valign="middle">Female sex–no. (%)</td><td align="center" valign="middle">5 (56)</td><td align="center" valign="middle">6 (75)</td><td align="center" valign="middle">3 (60)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Tobacco smoker–no. (%)</td><td align="center" valign="middle" style="border-bottom:solid thin">3 (33)</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td></tr><tr><td align="center" valign="middle">Coexisting conditions–no. (%)</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Good past health</td><td align="center" valign="middle">8 (89)</td><td align="center" valign="middle">4 (50)</td><td align="center" valign="middle">2 (40)</td></tr><tr><td align="center" valign="middle">Diabetes mellitus</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">1 (20)</td></tr><tr><td align="center" valign="middle">Hypertension</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">1 (13)</td><td align="center" valign="middle">2 (40)</td></tr><tr><td align="center" valign="middle">Hyperlipidaemia</td><td align="center" valign="middle">1 (11)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">1 (20)</td></tr><tr><td align="center" valign="middle">Atherosclerotic diseases</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">1 (20)</td></tr><tr><td align="center" valign="middle">Rheumatological conditions</td><td align="center" valign="middle">1 † (11)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td></tr><tr><td align="center" valign="middle">Malignancies</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">2 ‡ (40)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">History of haematological or solid organ transplantation</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td></tr><tr><td align="center" valign="middle">SARS-CoV-2 diagnosis</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Positive RT–PCR–no. (%)</td><td align="center" valign="middle">9 (100)</td><td align="center" valign="middle">8 (100)</td><td align="center" valign="middle">5 (100)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">CT values (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin">22.1 (18.1–29.0)</td><td align="center" valign="middle" style="border-bottom:solid thin">20.1 (15.1–21.7)</td><td align="center" valign="middle" style="border-bottom:solid thin">17.2 (15.7–22.8)</td></tr><tr><td align="center" valign="middle">COVID–19 disease severity</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Mild disease–no. (%)</td><td align="center" valign="middle">9 (100)</td><td align="center" valign="middle">8 (100)</td><td align="center" valign="middle">5 (100)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin">COVID–19-related OD, onset and duration (IQR)–days</td><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/></tr><tr><td align="center" valign="middle">Onset of OD from first COVID–19 symptom</td><td align="center" valign="middle">0.0 (0.0–7.0)</td><td align="center" valign="middle">4.0 (1.8–16.0)</td><td align="center" valign="middle">3.0 (0.0–3.0)</td></tr><tr><td align="center" valign="middle">Median duration of COVID–19-related OD</td><td align="center" valign="middle">159 (130.0–163.0)</td><td align="center" valign="middle">164.5 (118.3–180.3)</td><td align="center" valign="middle">138.0 (135.0–225.0)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin">COVID–19-related OD, symptomatology–no. (%)</td><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/></tr><tr><td align="center" valign="middle">OD onset</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Sudden</td><td align="center" valign="middle">6 (67)</td><td align="center" valign="middle">6 (75)</td><td align="center" valign="middle">1 (20)</td></tr><tr><td align="center" valign="middle">Gradual</td><td align="center" valign="middle">3 (33)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">4 (80)</td></tr><tr><td align="center" valign="middle">OD characteristics</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Anosmia</td><td align="center" valign="middle">4 (44)</td><td align="center" valign="middle">5 (63)</td><td align="center" valign="middle">2 (40)</td></tr><tr><td align="center" valign="middle">Hyposmia</td><td align="center" valign="middle">4 (44)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">3 (60)</td></tr><tr><td align="center" valign="middle">Parosmia</td><td align="center" valign="middle">1 (11)</td><td align="center" valign="middle">3 (38)</td><td align="center" valign="middle">0 (0)</td></tr><tr><td align="center" valign="middle">Hyperosmia</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Phantosmia ※</td><td align="center" valign="middle" style="border-bottom:solid thin">2 (22%)</td><td align="center" valign="middle" style="border-bottom:solid thin">1 (13)</td><td align="center" valign="middle" style="border-bottom:solid thin">0 (0)</td></tr><tr><td align="center" valign="middle">Olfactory assessments–mean (SD)</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Modified LK score</td><td align="center" valign="middle">0.7 (1.0)</td><td align="center" valign="middle">0.0 (0.0)</td><td align="center" valign="middle">0.0 (0.0)</td></tr><tr><td align="center" valign="middle">BTT</td><td align="center" valign="middle">2.9 (1.1)</td><td align="center" valign="middle">2.0 (1.1)</td><td align="center" valign="middle">1.8 (1.0)</td></tr><tr><td align="center" valign="middle">SIT </td><td align="center" valign="middle">24.6 (7.7)</td><td align="center" valign="middle">24.5 (6.3)</td><td align="center" valign="middle">19.6 (9.0)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin">SIT category–no. (%)</td><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/><td align="center" valign="middle" style="border-top:solid thin"/></tr><tr><td align="center" valign="middle">Normosmia</td><td align="center" valign="middle">1 (11)</td><td align="center" valign="middle">0 (0)</td><td align="center" valign="middle">0 (0)</td></tr><tr><td align="center" valign="middle">Mild microsmia</td><td align="center" valign="middle">1 (11)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">0 (0)</td></tr><tr><td align="center" valign="middle">Moderate microsmia</td><td align="center" valign="middle">3 (33)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">1 (20)</td></tr><tr><td align="center" valign="middle">Severe microsmia</td><td align="center" valign="middle">1 (11)</td><td align="center" valign="middle">2 (25)</td><td align="center" valign="middle">2 (40)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Anosmia</td><td align="center" valign="middle" style="border-bottom:solid thin">3 (33)</td><td align="center" valign="middle" style="border-bottom:solid thin">2 (25)</td><td align="center" valign="middle" style="border-bottom:solid thin">2 (40)</td></tr></tbody></table></div>Combination = oral vitamin A in combination with olfactory training (OT). Standard care = OT alone. Control = clinical observation. † Rheumatoid arthritis, quiescent disease. ‡ Malignancy of the breasts, in remission. ※ Phantosmia, detection of rotten substances or burning wood. BTT = butanol threshold test; COVID–19 = coronavirus disease 2019; CT = cycle threshold; Modified LK score = modified Lund-Kennedy endoscopic score; OD = olfactory dysfunction; RT–PCR = reverse transcription–polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SD = standard deviation; SIT = smell identification test.</transformed-table></extracted-table><extracted-table><table-id>brainsci-13-01014-t002</table-id><table-label>Table 2</table-label><table-caption>Intergroup analysis of interim (week 2) rs–fMRI brain scans (right caudate nucleus as the seed region).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="brainsci-13-01014-t002"><object-id pub-id-type="pii">brainsci-13-01014-t002_Table 2</object-id><label>Table 2</label><caption><p>Intergroup analysis of interim (week 2) rs–fMRI brain scans (right caudate nucleus as the seed region).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Olfactory Cortical Network Regions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peak z Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Combination group vs. standard care group</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Right gyrus rectus </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Combination group vs. control group</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Left anterior cingulate cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Right anterior cingulate cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Left superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Standard care group vs. control group</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Left anterior cingulate cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Left superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.0</td></tr></tbody></table><table-wrap-foot><fn><p>Two-sample <italic toggle="yes">t</italic> test. GRF correction (voxel-level <italic toggle="yes">p</italic> &lt; 0.010, cluster-level <italic toggle="yes">p</italic> &lt; 0.050). rs–fMRI = resting-state functional magnetic resonance imaging. Combination = oral vitamin A in combination with aerosolised diffuser olfactory training (OT). Control= clinical observation. Standard care = OT alone.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>brainsci-13-01014-t002_Table 2Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Intergroup analysis of interim (week 2) rs–fMRI brain scans (right caudate nucleus as the seed region).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Olfactory Cortical Network Regions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Cluster Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Peak z Value</th></tr></thead><tbody><tr><td align="center" valign="middle">Combination group vs. standard care group</td><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Right gyrus rectus </td><td align="center" valign="middle" style="border-bottom:solid thin">21</td><td align="center" valign="middle" style="border-bottom:solid thin">6.4</td></tr><tr><td align="center" valign="middle">Combination group vs. control group</td><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Left anterior cingulate cortex</td><td align="center" valign="middle">38</td><td align="center" valign="middle">5.0</td></tr><tr><td align="center" valign="middle">Right anterior cingulate cortex</td><td align="center" valign="middle">7</td><td align="center" valign="middle">4.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Left superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin">28</td><td align="center" valign="middle" style="border-bottom:solid thin">5.2</td></tr><tr><td align="center" valign="middle">Standard care group vs. control group</td><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle">Left anterior cingulate cortex</td><td align="center" valign="middle">24</td><td align="center" valign="middle">4.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Left superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin">20</td><td align="center" valign="middle" style="border-bottom:solid thin">6.0</td></tr></tbody></table></div>Two-sample t test. GRF correction (voxel-level p &lt; 0.010, cluster-level p &lt; 0.050). rs–fMRI = resting-state functional magnetic resonance imaging. Combination = oral vitamin A in combination with aerosolised diffuser olfactory training (OT). Control= clinical observation. Standard care = OT alone.</transformed-table></extracted-table><extracted-table><table-id>brainsci-13-01014-t003</table-id><table-label>Table 3</table-label><table-caption>Intergroup analysis of rs–fMRI brain scans (left caudate nucleus as the seed region).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="brainsci-13-01014-t003"><object-id pub-id-type="pii">brainsci-13-01014-t003_Table 3</object-id><label>Table 3</label><caption><p>Intergroup analysis of rs–fMRI brain scans (left caudate nucleus as the seed region).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Interim Assessment (Week 2)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">End-of-Treatment Assessment (Week 4)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OCN Regions</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cluster Size</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peak z Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OCN Regions</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cluster Size</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peak z Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Combination group vs. control group</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Right medial frontal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Left inferior frontal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Standard care group vs. control group</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Right superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Two-sample <italic toggle="yes">t</italic> test. GRF correction (voxel-level <italic toggle="yes">p</italic> &lt; 0.010, cluster-level <italic toggle="yes">p</italic> &lt; 0.050). rs–fMRI = resting-state functional magnetic resonance imaging. OCN = olfactory cortical network. Combination = oral vitamin A in combination with aerosolised diffuser olfactory training (OT). Control= clinical observation. Standard care = OT alone.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>brainsci-13-01014-t003_Table 3Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Intergroup analysis of rs–fMRI brain scans (left caudate nucleus as the seed region).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Interim Assessment (Week 2)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">End-of-Treatment Assessment (Week 4)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin">OCN Regions</th><th align="center" valign="middle" style="border-bottom:solid thin">Cluster Size</th><th align="center" valign="middle" style="border-bottom:solid thin">Peak z Value</th><th align="center" valign="middle" style="border-bottom:solid thin">OCN Regions</th><th align="center" valign="middle" style="border-bottom:solid thin">Cluster Size</th><th align="center" valign="middle" style="border-bottom:solid thin">Peak z Value</th></tr></thead><tbody><tr><td align="center" valign="middle">Combination group vs. control group</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Right medial frontal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin">23</td><td align="center" valign="middle" style="border-bottom:solid thin">5.6</td><td align="center" valign="middle" style="border-bottom:solid thin">Left inferior frontal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin">21</td><td align="center" valign="middle" style="border-bottom:solid thin">4.2</td></tr><tr><td align="center" valign="middle">Standard care group vs. control group</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">Right superior temporal gyrus</td><td align="center" valign="middle" style="border-bottom:solid thin">22</td><td align="center" valign="middle" style="border-bottom:solid thin">6.1</td><td align="center" valign="middle" style="border-bottom:solid thin">-</td><td align="center" valign="middle" style="border-bottom:solid thin">-</td><td align="center" valign="middle" style="border-bottom:solid thin">-</td></tr></tbody></table></div>Two-sample t test. GRF correction (voxel-level p &lt; 0.010, cluster-level p &lt; 0.050). rs–fMRI = resting-state functional magnetic resonance imaging. OCN = olfactory cortical network. Combination = oral vitamin A in combination with aerosolised diffuser olfactory training (OT). Control= clinical observation. Standard care = OT alone.</transformed-table></extracted-table></extracted-tables-set>